drugset
Drugs / pneumococcal 23v polysaccharide vaccine
last change Oct 2021 re-read 3 minutes ago

pneumococcal 23v polysaccharide vaccine

also known as PN23 · Pneumococcal Vaccine Polyvalent

Vaccine

Developed for
pneumococcal infection
Investigated by
Merck Sharp & Dohme LLC

Trials 1

today NCT00560950 · Ph 3
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00560950 Jul 2007 → May 2008 pneumococcal infection Merck Sharp & Dohme LLC Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2021-10-20 Merck Sharp & Dohme LLC CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option for Pneumococcal Vaccination in Appropriate Adults merck.com ↗
2014-08-13 Merck Sharp & Dohme LLC Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults merck.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as pneumococcal 23v polysaccharide vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00560950 ↗
Known as PN23 “In a study of older adults, first and second doses of 23-valent pneumococcal polysaccharide vaccine (PN23) induced IgG increases for all 8 vaccine serotypes tested.” PMID 21860256 ↗ Sep 2011
Known as Pneumococcal Vaccine Polyvalent “PNEUMOVAX(TM) 23 Vaccine (Pneumococcal Vaccine Polyvalent, Merck & Co., Inc.)” NCT00560950 ↗
Modality Vaccine “pneumococcal 23v polysaccharide vaccine” NCT00560950 ↗